Table 2.

Prescription rates (%) of lipid-lowering and/or antithrombotic drugs¹ in participants with a history of cardiovascular disease from the ISCOPE study (n = 1350).

	Age	Sex	Vulnerability2	CVD history3
≥ 85	75–84	female	male	yes	no	minor	major
(n = 347)	(n = 1003)	(n = 678)	(n = 672)	(n = 411)	(n = 927)	(n = 619)	(n = 731)
Optimal treatment (both drugs)	33	574	45	564	46	525	45	554
Suboptimal treatment
antithrombotic drug only	40	234	32	234	30	265	29	26
lipid-lowering drug only	2	5	5	3	3	4	5	3
Poor treatment (none of the two)	25	164	19	18	21	17	21	165

CVD: cardiovascular disease. ¹More than 270 days prescription of lipid-lowering and/or antithrombotic drugs in the year after start of ISCOPE study; ²assessed before screening (12 missing values); vulnerable (‘yes’) versus possibly vulnerable, not vulnerable participants, or do not know (together ‘no’); ³minor CVD: history of angina, transient ischaemic attack, and/or claudication; major CVD: history of myocardial infarction, stroke, and/or arterial surgery; ⁴Pearson’s chi-square p < 0.01 (as compared with ≥ 85 years, female, vulnerable or minor CVD, respectively); ⁵Pearson’s chi-square p < 0.05 (as compared with vulnerable, and as compared with minor CVD, respectively).